Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.51 |
| ▸ | ESRRA | P11474 | 4/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979660 | 0.77 | AR (0.54) | ARESRRASLC22A12 | |
| SCHEMBL21116323 | 0.76 | AR (0.53) | ARESRRASLC22A12CHEK1POLB | |
| SCHEMBL12594179 | 0.72 | AR (0.53) | AR | |
| SCHEMBL1978478 | 0.70 | AR (0.51) | ARESRRAALDH1A1MAPTKMT2A | |
| SCHEMBL18609983 | 0.69 | AR (0.47) | ARESRRASLC22A12L3MBTL1 | |
| SCHEMBL31060324 | 0.69 | AR (1.00) | ARALDH1A1POLBGAA | |
| SCHEMBL17354615 | 0.69 | AR (1.00) | ARALDH1A1POLBGAA | |
| SCHEMBL1644481 | 0.68 | AR (0.70) | AR | |
| SCHEMBL12727448 | 0.68 | AR (0.70) | AR | |
| SCHEMBL21963833 | 0.68 | AR (0.74) | ARSLC22A12ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | AR 4780/4885ESRRA 2386/4885SLC22A12 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.